Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
about
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myelomaThe role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursingMapping onto Eq-5 D for patients in poor health.PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.Surgical therapy of skeletal complications in multiple myeloma.Molecular monitoring of minimal residual disease in patients with multiple myeloma.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Cure of myeloma: hype or reality?Multiple myeloma: an update of developments in targeted therapy.Cure of multiple myeloma -- more hype, less reality.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Pharmacotherapy of multiple myeloma.Autologous stem cell transplantation beyond 60 years of age.A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.Melphalan: old and new uses of a still master drug for multiple myeloma.Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.Current status of autologous hematopoietic stem cell transplantation in myeloma.RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.Diagnosis and therapy of multiple myeloma.Therapeutic effects of thalidomide in hematologic disorders: a review.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.Controversies in multiple myeloma: to transplant or not?Autologous hematopoietic cell transplantation: an update for clinicians.Transplantation for Multiple Myeloma.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Current approaches to the initial treatment of symptomatic multiple myeloma.High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.Myeloma (multiple).Sequential, cycling maintenance therapy for post transplant multiple myeloma.Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma 2005.Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myelomaPoorex vivoinduction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma
P2860
Q33412636-C87B71B1-E98A-4A61-828D-DB1D29E612B0Q34361282-FA59E5A1-3EEE-4CC6-A474-1A286B4F04BEQ34408145-69A94F62-3096-401F-A3BA-1E4FC638A8C9Q34426066-21D30A51-7EA5-4F39-80BA-C3630ED1EC78Q34616652-AB283A3E-F09F-44EB-A9CB-242B71B3374AQ35197635-BEBFC1BE-12D1-4609-AD93-8E12E459E693Q35668677-06E0DA9F-4118-4320-B607-34A468375EB8Q35802414-169CC7FA-2709-44BD-B7A9-4ACF5160EE7DQ35949091-7EC04161-43E7-4C87-BCB1-2DD0114574CCQ36118436-5C813E23-4C22-4EBF-B29F-264253682A0AQ36301128-64AA6321-F6A7-46FF-9F58-C20C1CFBD9CDQ36407446-3150A765-BBA6-4835-92B6-B2BA9A2032EBQ36429735-D2FE8D4A-BC11-4D1C-8B49-9D5A29AB0508Q36623644-ED933AB7-16BE-4865-93FF-D39C67889087Q36654092-4EC0C7BB-C341-4474-837C-6E181DD3D870Q36902837-6F013785-0A1C-45E9-9790-E0A69173477DQ36916889-3B7B49FD-CF2E-4B20-B03E-68408B644B73Q37081473-2F11D83B-1E8B-4228-ABB8-0F9F165FF425Q37251047-E322E633-2697-459A-AE39-C12CDAC70525Q37268965-508FF56F-58CD-4BE4-B7F8-0E7BE49AF86CQ38107482-B2F72EBB-F9EC-461C-A740-683673AD7A03Q38121762-AA5AEAAA-73A2-46C4-8ACD-8B6903A6F6F8Q38148272-920C845C-A52A-4AC4-A621-143473BB1B94Q38242006-08103B8F-A907-49FF-9D1F-C719ADDCA0E9Q38248359-5F1CDCFF-207F-48E2-A9F7-2CCF7D3DF737Q38970603-577C1A94-8C21-48B4-B3A9-F51141F2B047Q39070193-884204B5-5ACA-4167-8736-C0F1F56F8333Q41819491-CD7301F1-C4FA-4E1F-857F-C936CEB7BD5BQ44712849-21896C02-E2B8-4452-96D6-40FA293227ABQ44908719-BEC127C5-0B64-4933-B99E-149B7FAB8A12Q46543501-4BCB5B4F-3986-4B61-81DB-6161DE1109C5Q46721437-19EAB22B-9B81-48E0-A65C-C6CE37DB0D6AQ46772649-E59AD1F2-165E-4CEA-824E-D82811749BC5Q47960020-B3C08776-D5D5-4250-81FF-97BA1404CD86Q48536821-92C08638-0F91-4E48-BBF7-9CF095F1D68EQ51067504-50EC403E-C681-4EE8-858A-729D2F10F53DQ53556535-CB52EA47-FF09-4A94-96A3-18ED1FB1FA64Q54977194-68DDD2E0-5E1B-48A1-B826-A3C3EA351019Q57209660-BB80457B-765C-4ECA-98EE-325E11354766Q57314084-56AF0983-4C30-4579-93A5-4E934EE444F5
P2860
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Overall and event-free surviva ...... tive randomized phase 3 study.
@en
Overall and event-free surviva ...... tive randomized phase 3 study.
@nl
type
label
Overall and event-free surviva ...... tive randomized phase 3 study.
@en
Overall and event-free surviva ...... tive randomized phase 3 study.
@nl
prefLabel
Overall and event-free surviva ...... tive randomized phase 3 study.
@en
Overall and event-free surviva ...... tive randomized phase 3 study.
@nl
P2093
P1433
P1476
Overall and event-free surviva ...... tive randomized phase 3 study.
@en
P2093
Alexandra J Croockewit
Bronno van der Holt
Christine M Segeren
Douwe H Biesma
Dutch-Belgian Hemato-Oncology Cooperative Study Group
Edo Vellenga
Gregor E G Verhoef
Harry C Schouten
Henk M Lokhorst
Ivon Buijt
P304
P356
10.1182/BLOOD-2002-03-0889
P407
P577
2002-11-27T00:00:00Z